Enlivex (ENLV) Non-Current Deferred Tax Liability (2018 - 2025)
Enlivex (ENLV) posted quarterly Non-Current Deferred Tax Liability of $382.6 million for Q4 2025, up 54176.03% quarter-over-quarter from $705000.0 in Q4 2022.
Enlivex (ENLV) Non-Current Deferred Tax Liability (2018 - 2025) Analysis & Trends
Enlivex's Non-Current Deferred Tax Liability history runs 6 years deep, the most recent figure standing at $382.6 million for Q4 2025.
- In Q4 2025, Non-Current Deferred Tax Liability changed N/A year-over-year to $382.6 million; the TTM figure through Dec 2025 stood at $382.6 million (changed N/A YoY), while the FY2025 annual figure was $382.6 million, changed N/A from the prior year.
- Non-Current Deferred Tax Liability for Q4 2025 stood at $382.6 million, up from $705000.0 in the prior quarter.
- The five-year high for Non-Current Deferred Tax Liability was $382.6 million in Q4 2025, with the low at $705.0 in Q4 2021.
- The 3-year median for Non-Current Deferred Tax Liability is $705000.0 (2022), against an average of $127.8 million.
- The sharpest annual moves came in 2021 and 2022: Non-Current Deferred Tax Liability tumbled 99.9% in 2021, then surged 99900.0% in 2022.
- Enlivex's Non-Current Deferred Tax Liability stood at $705.0 in 2021, then soared by 99900.0% to $705000.0 in 2022, then surged by 54176.03% to $382.6 million in 2025.
- Business Quant data shows ENLV's Non-Current Deferred Tax Liability at $382.6 million in Q4 2025, $705000.0 in Q4 2022, and $705.0 in Q4 2021.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Enlivex | 4.51 Mn | -1.25 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 382.65 Mn |
| Dec 31, 2025 | 382.65 Mn |
| Dec 31, 2022 | 705,000.00 |
| Dec 31, 2022 | 705,000.00 |
| Dec 31, 2021 | 705.00 |
| Dec 31, 2021 | 705.00 |
| Dec 31, 2020 | 682,000.00 |
| Dec 31, 2020 | 682,000.00 |
| Dec 31, 2019 | 635,000.00 |
| Dec 31, 2019 | 635,000.00 |
| Dec 31, 2018 | 222,000.00 |
| Dec 31, 2018 | 222,000.00 |